These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 10620545

  • 1. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy.
    Stigant CE, Cohen J, Vivera M, Zaltzman JS.
    Am J Kidney Dis; 2000 Jan; 35(1):58-63. PubMed ID: 10620545
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin-converting enzyme inhibitors after renal transplantation.
    Bravo P, Felgueiras J, Santos C, Oliveira C, Ponce P.
    Transplant Proc; 2008 Apr; 40(3):740-2. PubMed ID: 18455003
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period.
    Formica RN, Friedman AL, Lorber MI, Bia MJ.
    Transplant Proc; 2004 Nov; 36(9):2675-8. PubMed ID: 15621121
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
    Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, Oberbauer R.
    J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
    [Abstract] [Full Text] [Related]

  • 5. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients.
    Suwelack B, Kobelt V, Erfmann M, Hausberg M, Gerhardt U, Rahn KH, Hohage H.
    Transpl Int; 2003 May; 16(5):313-20. PubMed ID: 12759722
    [Abstract] [Full Text] [Related]

  • 6. Is it time for ACE inhibitors in chronic allograft nephropathy?
    Lewis JB, Helderman JH.
    Am J Kidney Dis; 2000 Jan; 35(1):154-6. PubMed ID: 10620559
    [No Abstract] [Full Text] [Related]

  • 7. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the early period after kidney transplantation.
    Orlić L, Mikolasević I, Sladoje-Martinović B, Bubić I, Pavletić-Persić M, Racki S.
    Coll Antropol; 2013 Sep; 37(3):809-14. PubMed ID: 24308221
    [Abstract] [Full Text] [Related]

  • 8. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients.
    Hillebrand U, Suwelack BM, Loley K, Lang D, Reuter S, Amler S, Pavenstädt H, Hausberg M, Büssemaker E.
    Transpl Int; 2009 Nov; 22(11):1073-80. PubMed ID: 19624495
    [Abstract] [Full Text] [Related]

  • 9. The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy.
    Zaltzman JS, Nash M, Chiu R, Prasad R.
    Nephrol Dial Transplant; 2004 Apr; 19(4):940-4. PubMed ID: 15031353
    [Abstract] [Full Text] [Related]

  • 10. Effect of calcium channel antagonists on renal function in hypertensive heart transplant recipients.
    Bunke M, Ganzel B.
    J Heart Lung Transplant; 1992 Apr; 11(6):1194-9. PubMed ID: 1457446
    [Abstract] [Full Text] [Related]

  • 11. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M.
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [Abstract] [Full Text] [Related]

  • 12. [A prospective study on the cough mechanism induced by angiotensin-converting enzyme inhibitors in patients with hypertension].
    Ye RJ, He QY, Gai J, Shang Y.
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Sep; 27(9):581-4. PubMed ID: 15498266
    [Abstract] [Full Text] [Related]

  • 13. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
    Montanaro D, Gropuzzo M, Tulissi P, Vallone C, Boscutti G, Mioni R, Risaliti A, Baccarani U, Adani GL, Sainz M, Bresadola F, Mioni G.
    Transplant Proc; 2005 Mar; 37(2):991-3. PubMed ID: 15848600
    [Abstract] [Full Text] [Related]

  • 14. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
    J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
    [Abstract] [Full Text] [Related]

  • 15. Renal allograft protection with early angiotensin-converting enzyme inhibitors administration.
    Montanaro D, Gropuzzo M, Tulissi P, Boscutti G, Mioni R, Risaliti A, Baccarani U, Adani GL, Sainz M, Bresadola F, Mioni G.
    Transplant Proc; 2004 Apr; 36(3):692-4. PubMed ID: 15110633
    [Abstract] [Full Text] [Related]

  • 16. [Polymorphism studies of angiotensin converting enzyme gene in chronic glomerulonephritis].
    Kutyrina IM, Tareeva IE, Nosikov VV, Kamyshova ES, Gorashko NM, Chistiakov DA, Okonova EB, Troepol'skaia OV.
    Ter Arkh; 1999 Apr; 71(6):30-4. PubMed ID: 10420452
    [Abstract] [Full Text] [Related]

  • 17. Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study.
    Kessler M, Hestin D, Mayeux D, Mertes PM, Renoult E.
    Clin Nephrol; 1996 Feb; 45(2):83-9. PubMed ID: 8846535
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
    Seeman T, Pohl M, Misselwitz J, John U.
    Kidney Blood Press Res; 2009 Feb; 32(6):440-4. PubMed ID: 20016211
    [Abstract] [Full Text] [Related]

  • 19. [Clinical effects of trandolapril in chronic glomerulonephritis patients with renal insufficiency].
    Yoshida A, Takeda A, Fukuda M, Toda S, Morozumi K.
    Nihon Jinzo Gakkai Shi; 2000 May; 42(4):333-7. PubMed ID: 10897592
    [Abstract] [Full Text] [Related]

  • 20. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ, Ishola DA, Akintomide AO, Ajayi AA.
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.